en · de · es · fr · pt
liraglutide-notes.peptides1004.com › Blog › Identity And Chemical Background — Field Notes

Identity And Chemical Background — Field Notes

By Editorial Desk · published 2025-08-15 · last reviewed 2025-10-01 · Blog

Everything below concerns HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2025-10-01. Numbers and descriptions here follow the published literature rather than marketing material.

Identity and Chemical Background

Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.

Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.

PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.

Bremelanotide Identity and Background

Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.

Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.

Pt-141 at a glance

PropertyValueNotes
Chemical classCyclic heptapeptideSynthetic melanocortin analogue
Molecular formulaC50H68N14O10Corresponds to a mass near 1025 daltons
AppearanceWhite to off-white powderLyophilised solid before reconstitution
SolubilitySoluble in water and polar solventsPoor solubility in nonpolar media
Common synonymsBremelanotide, PT-141Code name and international name used interchangeably

Bremelanotide Background And Development

Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.

Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.

Related pages on this site

Chemical Identity of Bremelanotide

Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.

PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.

Peptide Handling and Storage Practice

Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.

Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.

Receptor Mechanism and Trial Evidence

Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.

Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.

Supporting material

== Terminology == "Redox" is a portmanteau of "reduction" and "oxidation". The term first appeared in a 1928 article by Leonor Michaelis and Louis B. Flexner. Oxidation is a process in which a substance loses electrons. Reduction is a process in which a substance gains electrons. The processes of oxidation and reduction occur simultaneously and cannot occur independently. In redox processes, the reductant transfers electrons to the oxidant. Thus, in the reaction, the reductant or reducer or reducing agent loses electrons and is oxidized, while the oxidant or oxidizer or oxidizing agent gains electrons and is reduced. The pair of an oxidizing and reducing agent that is involved in a particular reaction is called a redox pair. A redox couple is a reducing species and its corresponding oxidizing form, e.g., Fe2+/ Fe3+.The oxidation alone and the reduction alone are each called a half-reaction because two half-reactions always occur together to form a whole reaction. In electrochemical reactions the oxidation and reduction processes do occur simultaneously but are separated in space. Although oxidation is commonly associated with forming oxides, other chemical species can serve the same function; in hydrogenation, bonds such as C=C are reduced by the transfer of hydrogen atoms.

In chemistry, a hydrogen bond (H-bond) is a specific type of molecular interaction that exhibits partial covalent character and cannot be described as a purely electrostatic force. It occurs when a hydrogen (H) atom, covalently bonded to a more electronegative donor atom or group (Dn), interacts with another electronegative atom bearing a lone pair of electrons—the hydrogen bond acceptor (Ac). Unlike simple dipole–dipole interactions, hydrogen bonding arises from charge transfer (nB → σ*AH), orbital interactions, and quantum mechanical delocalization, making it a resonance-assisted interaction rather than a mere electrostatic attraction. The general notation for hydrogen bonding is Dn−H···Ac, where the solid line represents a polar covalent bond, and the three dots indicate the hydrogen bond. Hydrogen bond donors have a protic hydrogen attached to an electronegative atom such as nitrogen (N), oxygen (O), and fluorine (F). Hydrogen bond acceptors have a lone pair of electrons, such as the nitrogen atom of amines and amides and the oxygen atom of carboxylates and water. The term "hydrogen bond" is generally used for well-defined, localized interactions with significant charge transfer and orbital overlap, such as those in DNA base pairing or ice. In contrast, "hydrogen-bonding interactions" is a broader term used when the interaction is weaker, more dynamic, or delocalized, such as in liquid water, supramolecular assemblies (e.g.: lipid membranes, protein-protein interactions), or weak C-H···O interactions.

== Binding (drug distribution) == A drug in blood exists in two forms: bound and unbound. Depending on a specific drug's affinity for plasma proteins, a proportion of the drug may become bound to the proteins, with the remainder being unbound. If the protein binding is reversible, then a chemical equilibrium will exist between the bound and unbound states, such that:

== History == Rupatadine discovery, pre-clinical and clinical development was performed by Uriach, a Spanish pharmaceutical company. It was launched in 2003 in Spain under the brand name of Rupafin. It was launched in Canada under the name Rupall.

American Association of Physical Anthropologists Biological Anthropology Section of the American Anthropological Association British Association of Biological Anthropologists and Osteoarchaeologists Canadian Association for Physical Anthropology Journals

Sources: en.wikipedia.org

Notes from published material

== Measuring vapor == Since it is in the gas phase, the amount of vapor present is quantified by the partial pressure of the gas. Also, vapors obey the barometric formula in a gravitational field, just as conventional atmospheric gases do.

Incandescent lights are filled with argon, to preserve the filaments at high temperature from oxidation. It is used for the specific way it ionizes and emits light, such as in plasma globes and calorimetry in experimental particle physics. Gas-discharge lamps filled with pure argon provide lilac/violet light; with argon and some mercury, blue light. Argon is also used for blue and green argon-ion lasers.

=== Research === Animal models are able to recapitulate some aspects of antidepressant withdrawal. For example, discontinuation of paroxetine in mice leads to anxiety-like behavior, together with a rebound over-activation of 5-HT neurons. One problem is that many animal studies use fluoxetine as the study drug, despite it being not very commonly associated with withdrawal in human patients. A lack of understanding over how antidepressants work also complicates the picture. More studies using more relevant drugs, along with measuring more relevant aspects of the nervous system, will be needed to understand the mechanism of withdrawal in rodents.

== Fourth round proper == The draw for the fourth round was made on 8 January 2023, consisting of the 32 winners from the previous round. The round included one team from the fifth tier, the lowest-ranked team remaining in the competition: Wrexham.

Sources: en.wikipedia.org

Background from the literature

the Kurchatov Institute, Russia's leading research and development institution in nuclear energy, where the first nuclear reactor in Europe was built the Landau Institute for Theoretical Physics the Institute for Theoretical and Experimental Physics the Kapitza Institute for Physical Problems the Steklov Institute of Mathematics The city contains 452 libraries, including 168 for children. The Russian State Library, founded in 1862, is the national library of Russia. This library contains more than 275 kilometers (171 mi) of shelves and 42 million items—including more than 17 million books and serial volumes, 13 million journals, 350,000 music scores and sound records, and 150,000 maps—making it the country's largest library and one of the world's largest. Items in 247 languages other than Russian account for 29% of the library's collection. The State Public Historical Library, founded in 1863, is the largest library specialising in Russian history. Its collection contains four million items in 112 languages, mostly on Russian and world history, heraldry, numismatics, and the history of science. On the subject of primary and secondary education, journalist Clifford J. Levy of The New York Times newspaper wrote in 2011:

=== MicroRNAs === MicroRNAs are a factor in the development of that type of disease. MicroRNAs usually operate as a negative regulator of the expression of target proteins, and their increased concentration after biologic treatment (bDMARDs) or after anti-rheumatic drugs. The levels of miRNA before and after anti-TNFa/DMRADs combination therapy are potential novel biomarkers for predicting and monitoring the outcome. For instance, some of them were found significantly upregulated by anti-TNFa/DMRADs combination therapy. For example, miRNA-16-5p, miRNA-23-3p, miRNA125b-5p, miRNA-126-3p, miRNA-146a-5p, miRNA-223-3p. Curious fact is that only responder patients showed an increase in those miRNAs after therapy, and paralleled the reduction of TNFα, interleukin (IL)-6, IL-17, rheumatoid factor (RF), and C-reactive protein (CRP).

==== Towards an energetic definition of civilization ==== In 1980, Nikolai Kardashev published a second article entitled Strategies of Searching for Extraterrestrial Intelligence: A Fundamental Approach to the Basic Problem, in which he stated that:Detection and studies of extraterrestrial civilizations constitute a problem of immense significance for the progress of humanity and for its culture and philosophy. The discovery of intelligent life in the Universe would provide a guideline to the possible development of our civilization over astronomical time spans.

By late 2019, disagreements emerged within Pakatan Harapan about Mahathir's planned handover of power to Anwar Ibrahim, eventually culminating in a political crisis in 2020. Mahathir and a faction of the coalition felt that Anwar would be unable to command a parliamentary majority. MPs supporting Anwar demanded a timeframe for Mahathir's resignation and handover of power. In February 2020, MPs opposed to Anwar taking over met and agreed to form a new government. Anwar told the media that he had been "betrayed". Anwar and Mahathir met to clarify the situation, where Mahathir insisted he had no involvement in a new government. Mahathir, refusing to work with UMNO leaders, submitted his resignation to the Agong, Abdullah of Pahang, on 24 February 2020. The Agong appointed him interim prime minister until a replacement could be agreed. BERSATU President Muhyiddin Yassin declared the party's withdrawal from Pakatan Harapan; Mahathir also resigned from the party in response. The next day, Mahathir reported to work as usual in his new role as caretaker prime minister. During his interim premiership, he introduced the 2020 Economic Stimulus Package to counter the economic impact of COVID-19, based on three strategies: mitigating its impact, spurring people-centric economic growth, and promoting quality investments. On 29 February, the Agong appointed Muhyiddin prime minister, determining that he was most likely to be able to hold the support of a majority in parliament.

Apart from the long history, cod differ from most fish because the fishing grounds are far from population centres. The large cod fisheries along the coast of North Norway (and in particular close to the Lofoten islands) have been developed almost uniquely for export, depending on sea transport of stockfish over large distances. Since the introduction of salt, dried and salted cod (clipfish or 'klippfisk' in Norwegian) has also been exported. By the end of the 14th century, the Hanseatic League dominated trade operations and sea transport, with Bergen as the most important port. William Pitt the Elder, criticizing the Treaty of Paris in Parliament, claimed cod was "British gold"; and that it was folly to restore Newfoundland fishing rights to the French. In the 17th and 18th centuries in the New World, especially in Massachusetts and Newfoundland, cod became a major commodity, creating trade networks and cross-cultural exchanges. In 1733, Britain tried to gain control over trade between New England and the British Caribbean by imposing the Molasses Act, which they believed would eliminate the trade by making it unprofitable. The cod trade grew instead, because the "French were eager to work with the New Englanders in a lucrative contraband arrangement". In addition to increasing trade, the New England settlers organized into a "codfish aristocracy". The colonists rose up against Britain's "tariff on an import". In the 20th century, Iceland re-emerged as a fishing power and entered the Cod Wars.

Sources: en.wikipedia.org

Frequently asked questions

What is PT-141?

PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.

Is PT-141 a steroid or a hormone?

It is neither a steroid nor a naturally occurring human hormone. Bremelanotide is a manufactured peptide that mimics part of the melanocortin signalling system by binding receptor proteins. Its effects come from receptor activation, not from replacing a circulating hormone.

Why does the ring structure matter?

The internal lactam bridge locks the peptide into a defined shape, which raises receptor affinity and slows enzymatic breakdown. Linear versions of the same sequence are less stable and bind more weakly. Ring geometry is therefore central to how the molecule behaves in the body.

What class of compound is this?

It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.

Network